



## Curriculum Vitae

Personal information **Christine Aardal**

Work experience

---

2013 – Present, **Senior Scientist, Norwegian Institute of Public Health**, Division for Infection Control and Preparedness, Oslo, Norway – co-lead of the access work package for the second European Union's Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI-2); co-lead of the research and innovation work package for EU-JAMRAI-1; co-lead in the EU-financed Innovative Medicines Initiative project, Driving reinvestment in R&D for antibiotics and advocating their responsible use (DRIVE-AB); co-lead for the Programme Committee of the Oslo Medicines Initiative; lead of the TATFAR (TransAtlantic TaskForce on Antibiotic Resistance) working group on ensuring access and innovation of antibiotics, expert to the Norwegian assessment of local production for critical antibiotics; researcher on a research project regarding medicines supply surety (Measures for Improved Availability of Medicines and Vaccines – MIA), member of the World Health Organization expert review panel for the overall programme review of Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property; expert input to the Norwegian Development Agency for various topics such as Unitaid, research areas are AMR-related innovation and access to technologies, including older, critical antibiotics.

2012 – 2013, **Senior Advisor, Norwegian Agency for Development Cooperation (Norad)**, Oslo, Norway – Seconded from the Knowledge Center to lead Norad's participation in the UN Commission of Life-Saving Commodities for Women and Children

2009 – 2013, **Researcher, Norwegian Knowledge Center for Health Services**, Oslo, Norway –researched innovative business models to assist low-income countries in regards to the development of and access to health technologies. Årdal was a member of the Secretariat for WHO's Consultative Expert Working Group on Research and Development: Financing and Coordination.

2005 – 2009, **Manager, Ernst & Young**, Oslo, Norway – an international professional services firm – consulted for clients on a variety of topics with a primary focus in healthcare.

2001 – 2005, **Consultant, Webstar Health**, London, United Kingdom –

a healthcare consulting and technology company specializing in delivering pharmacy-based solutions to the National Health Service, pharmaceutical manufacturers and pharmacy organizations.

1995 – 1999, **Project Manager** (and other roles) at **PCS Health Systems**, Minnesota, USA – a former subsidiary of Eli Lilly & Company; a prescription benefit management company insuring the medicines use of over 50 million Americans.

## Education and training

---

2009 – 2017, **Ph.D.**, University of Oslo, Faculty of Medicine, Institute of Health and Society, Norway

1999 – 2001, **Master of Business Administration**, Rotterdam School of Management, Erasmus University, Rotterdam, The Netherlands

1990 – 1994, **Bachelor of Science in Business**, Carlson School of Management, University of Minnesota, Minneapolis, Minnesota, U.S.A.

## Additional information

---

### Publications

1. Alvarez RD, Årdal C, Classen AY, Nagel TE, Ceyskens P-J, German GJ. Cross-border dialogue: An international survey of regulators on phage therapy. *International Journal of Antimicrobial Agents*, September 6, 2025. <https://doi.org/10.1016/j.ijantimicag.2025.107614>
2. Sharma T, Kruja K, Årdal C, Lopert R, Mestre-Ferrandiz J, Boselli S, Vogler S. Managing costly new drugs to support equitable access: international collaboration and patient engagement to assess value, and managed entry agreements. *BMJ* 2025; 391 doi: <https://doi.org/10.1136/bmj-2025-086174>
3. Moon K, Coxon C, Årdal C, Botgros R, Djebara S, Durno L, Fiore CR, Perrin J-P, Dixon DM, Cavaleri M. Considerations and perspectives on phage therapy from the transatlantic taskforce on antimicrobial resistance. *Nat Commun* **16**, 10883 (2025). <https://doi.org/10.1038/s41467-025-64608-3>.
4. Davido B, Ny S, van Lingen C, Årdal C, et al. Strengthening antimicrobial resistance governance in Europe: a coordinated one health approach, *The Lancet Regional Health - Europe*, 2025, 101540, ISSN 2666-7762, <https://doi.org/10.1016/j.lanepe.2025.101540>.
5. Jahre M, van Oorschot K, Årdal C, Sverrisson E, Pettersen M, Wangen A. Sustainable Pharmaceutical Procurement: Environmental tendering criteria for better or worse? *Journal of Purchasing and Supply Management*, 2025, <https://doi.org/10.1016/j.pursup.2025.101081>.
6. Melaku T, Mekonnen Z, Tucho GT, Viana J, Årdal C, Jahre M. Resilience and Adaptability in Paracetamol Supply Chains: A Systems Perspective on COVID-19 Challenges and Responses in Ethiopia. *Logistics* 2025, 9, 15. <https://doi.org/10.3390/logistics9010015>
7. Årdal C, Gawad M, Baraldi E, Jahre M, Edlund C. Fragmented markets for older antibiotics and child formulations, Denmark, Norway, Sweden. *Bull World Health Organ.* 2025 Jan 1;103(1):51–6. doi: 10.2471/BLT.24.292102. Epub 2024 Dec 3. PMID: PMC11704633.
8. Weber B, Ritchie N, Hilker S, Chan D, Peukert C, Deisinger J, Ives R, Årdal C, Burrows L, Brønstrup M, Magolan J, Raivio T, Brown E. High-Throughput Discovery of Synthetic Siderophores for

- Trojan Horse Antibiotics. ACS Infectious Diseases, Oct 22, 2024. <https://doi.org/10.1021/acscinfecdis.4c00359>
9. Panteli, D., Anderson, M., Fieldman, T. Baraldi E, Tängdén T, Vogler S, Årdal C, Mossialos E. Policy options for sustainable access to off-patent antibiotics in Europe. *npj Antimicrob Resist* 2, 40 (2024). <https://doi.org/10.1038/s44259-024-00061-4>
  10. Mekonnen Z, Melaku T, Tucho GT, Mecha M, Årdal C, Jahre M. Availability of essential, generic medicines before and during COVID-19 at selected public pharmaceutical supply agencies in Ethiopia: a comparative cross-sectional study *BMJ Open* 2024;14:e077545. doi:10.1136/bmjopen-2023-077545
  11. Selviaridis K, Dube N, Årdal C, de Vries H. Promoting resilience in medicine supply chains: An exploration of the role of contracting. *EurOMA* 2022. <https://eprints.lanacs.ac.uk/id/eprint/173348/>
  12. Baraldi E, Årdal C, Aho E, Popescu G-A, Melaku T. The multifaceted nature of lack of access to antibiotics: types of shortage and specific causes, consequences, and solutions. *Clinical Microbiology and Infection*, 2024, <https://doi.org/10.1016/j.cmi.2024.11.012>.
  13. Årdal C, Baraldi E, Busse R, Castro R, Ciabuschi F, Cisneros JM, Gyssens IC, Harbarth S, Kostyanov T, Lacotte Y, Magrini N, McDonnell A, Monnier AA, Moon S, Mossialos E, Peñalva G, Ploy M-C, Radulović M, Alonso Ruiz A, Røttingen J-R, Sharland M, Tacconelli E, Theuretzbacher U, Vogler S, Wolff Sönksen U, Åkerfeldt K, Cars O, O'Neill J. Transferable exclusivity voucher: a flawed incentive to stimulate antibiotic innovation. *The Lancet*, Feb 8, 2023, [https://doi.org/10.1016/S0140-6736\(23\)00282-9](https://doi.org/10.1016/S0140-6736(23)00282-9)
  14. Årdal C. Market stimulation needed for predictable supply of antibiotics with vulnerable supply chains in Europe. *Antimicrobial Viewpoints*, May 10, 2023, <https://revive.gardp.org/market-stimulation-needed-for-predictable-supply-of-antibiotics-with-vulnerable-supply-chains/>
  15. Mekonnen Z, Melaku T, Tucho GT, Mecha M, Årdal C, Jahre M. The knock-on effects of COVID-19 pandemic on the supply and availability of generic medicines in Ethiopia: mixed methods study. *BMC Health Serv Res* 23, 513 (2023). <https://doi.org/10.1186/s12913-023-09535-z>
  16. Ahlqvist V, Dube N, Jahre M, Lee J, Melaku T, Moe A, Olivier M, Selviaridis K, Viana J, Årdal C. Supply chain risk management strategies in normal and abnormal times: Policymakers' role in reducing generic medicine shortages. *International Journal of Physical Distribution & Logistics Management*, Sept 28, 2022, <https://doi.org/10.1108/IJPDLM-12-2021-0511>
  17. Årdal C, Lopert R, Mestre-Ferrandiz J. Overview of the Market for Novel Medicines in the WHO European Region. *Oslo Medicines Initiative*, 2022. <https://www.ncbi.nlm.nih.gov/books/NBK587850/>
  18. Colson A, Morton A, Årdal C, Chalkidou K, Davies S, Garrison L, Jit M, Laxminarayan R, Megiddo I, Morel C, Nonvignon J, Outtersson K, Rex JH, Sarker AR, Schulpher M, Woods B, Xiao Y. Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem? *Value in Health*, Sept 18, 2021. Doi: <https://doi.org/10.1016/j.jval.2021.06.002>
  19. Outtersson K, Orubu ESF, Rex J, Årdal C, Zaman MH. Patient access in fourteen high-income countries to new antibacterials approved by the FDA, EMA, PMDA, or Health Canada, 2010-2020, *Clinical Infectious Diseases*, 2021;, ciab612, <https://doi.org/10.1093/cid/ciab612>
  20. Årdal, C.; Lacotte, Y.; Edwards, S.; Ploy, M.-C.; on behalf of the European Union Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections. National Facilitators and Barriers to the Implementation of Incentives for Antibiotic Access

- and Innovation. *Antibiotics* 2021, 10, 749.  
<https://doi.org/10.3390/antibiotics10060749>
21. Morel C, Alm R, Årdal C, Bandera A, Bruno G, Carrara E, Colombo G, de Kraker M, Essack S, Frost I, Gonzalez-Zorn HB, Guardabassi L, Harbarth S, Jørgensen PS, Kanj S, Kostyanev T, Laxminarayan R, Leonard F, Levy Hara G, Mendelson M, Mikulska M, Mutter NT, Outterson K, Rodriguez Baño J, Scudeller L, Tacconelli E. A one health framework to estimate the cost of antimicrobial resistance. *Antimicrob Resist Infect Control* **9**, 187 (2020). <https://doi.org/10.1186/s13756-020-00822-6>
  22. Årdal C, Baraldi E, Beyer P, Cooke E, Lacotte Y, Larsson DGJ, Ploy M-C, Røttingen J-A, Smith I. Supply chain transparency needed to enable sustainable and continuous supply of essential medicines. *Bull World Health Organ* 2021 March 10 doi: 10.2471/BLT.20.267724
  23. Årdal C, McAdams D, Wester AL, Møgedal S. Multi-purposing environmental polio surveillance for AMR. *Bull World Health Organ* 2021;99:239–240 <http://dx.doi.org/10.2471/BLT.20.258905>
  24. Kållberg C, Hudson J, Salvesen Blix H, Årdal C, Klein E, Lindbæk M, Outterson K, Røttingen J-A, Laxminarayan R. The effect of generic market entry on antibiotic prescriptions in the United States. *Nat Commun* **12**, 2937 (2021).  
<https://doi.org/10.1038/s41467-021-23049-4>
  25. Lacotte Y, Årdal C, Ploy M-C. Infection prevention and control research priorities: what do we need to combat healthcare-associated infections and antimicrobial resistance? *Antimicrob Resist Infect Control* **9**, 142 (2020).  
<https://doi.org/10.1186/s13756-020-00801-x>
  26. Monnier A, Tacconelli E, Årdal C, Cavaleri M, Gyssens I. A case study on *Staphylococcus aureus* bacteraemia: available treatment options, antibiotic R&D and responsible antibiotic-use strategies. *JAC-Antimicrobial Resistance*, Volume 2, Issue 2, June 2020, dlaa034, <https://doi.org/10.1093/jacamr/dlaa034>
  27. Årdal C, Lacotte Y, Ploy M-C. Financing pull mechanisms for antibiotic-related innovation: Opportunities for Europe. *Clinical Infection Diseases* (2020). <https://doi.org/10.1093/cid/ciaa153>
  28. Årdal C, Balasegaram M, Laxminarayan R, McAdams D, Outterson K, Rex JH, Sumpradit N. Antibiotic development — economic, regulatory and societal challenges. *Nature Reviews Microbiology* (2019) doi:10.1038/s41579-019-0293-3.
  29. Storehagen Dansie L, Odoch W, Årdal C. Industrial Perceptions of Medicine Regulatory Harmonization in the East African Community. *PLoS ONE* (2019) 14(6): e0218617.  
<https://doi.org/10.1371/journal.pone.0218617>
  30. Kållberg C, Årdal C, Salvesen Blix H, Klein E, M. Martinez E, Lindbæk M, et al. Introduction and geographic availability of new antibiotics approved between 1999 and 2014. *PLoS ONE* (2018) 13(10): e0205166. <https://doi.org/10.1371/journal.pone.0205166>
  31. Monnier A, Schouten J, Tebano G, Zanichelli V, Huttner B, Pulcini C, Årdal C, Harbarth S, Hulscher M, Gyssens I. Ensuring Antibiotic Development, Equitable Availability, and Responsible Use of Effective Antibiotics: Recommendations for Multisectoral Action. *Clinical Infectious Diseases*, 26 Sept 2018.  
<https://doi.org/10.1093/cid/ciy824>
  32. Storehagen L, Aftab F, Årdal C, Savic M, Røttingen JA. Should Antibiotics Be Controlled Medicines? Lessons from the Controlled Drug Regimen. *The Journal of Law, Medicine & Ethics*. July 17, 2018.
  33. Årdal C, Johnsen J, Johansen K. Designing a Delinked Incentive for Critical Antibiotics: Lessons from Norway. *The Journal of Law, Medicine & Ethics*. July 17, 2018.

34. Savic M, Årdal C. A Grant Framework as a Push Incentive to Stimulate Research and Development of New Antibiotics. *The Journal of Law, Medicine & Ethics*. July 17, 2018.
35. Baraldi E, Lindahl O, Savic M, Findlay D, Årdal C. Antibiotic Pipeline Coordinators. *The Journal of Law, Medicine & Ethics*. July 17, 2018.
36. Årdal C, Baraldi E, Theuretzbacher U, Outterson K, Plahte J, Ciabuschi F, Røttingen J-A. Insights into early stage antibacterial development in small and medium sized enterprises: a survey of targets, costs, and durations. *Journal of Pharmaceutical Policy and Practice* 2018;11:8.
37. Winkler A, Schmutzhard E, Årdal C, Spencer P. Nodding Syndrome— An Investment Case for Global Health? *J Neuroinfect Dis* 9: 273. doi:10.4172/2314-7326.1000273.
38. Årdal C, Baraldi E, Ciabuschi F, Outterson K, Rex JH, Piddock LJV, Findlay D. To the G20: incentivising antibacterial research and development. *The Lancet Infectious Diseases*, Volume 17, Issue 8, 799 – 801.
39. Årdal, Røttingen J-A, Opalska A, van Hengel AJ, Larsen J. Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance, *Clinical Infectious Diseases*, 7 June 2017.
40. Theuretzbacher U, Savic M, Årdal C, Harbarth S. Market watch: Innovation in the preclinical antibiotic pipeline. *Nature Reviews Drug Discovery* 2017;16:744.
41. Theuretzbacher U, Årdal C, Harbarth S. Linking sustainable use policies to novel economic incentives to stimulate antibiotic research and development. *ID Reports* 2017;9(1).
42. Årdal C, et al. An antibiotic's journey from marketing authorization to use, Norway. *Bull World Health Organ* 2017;95:220–226
43. Årdal C, Røttingen JA. Financing and collaboration on research and development for nodding syndrome. *Health Res Policy Syst*. 2016 Mar 17;14(1):19.
44. Nwokoro E, Leach R, Årdal C, Baraldi E, Ryan K, Plahte J. An assessment of the future impact of alternative technologies on antibiotics markets. *Journal of Pharmaceutical Policy and Practice* 2016;9:34.
45. Årdal C, Outterson K, et al. International cooperation to improve access to and sustain effectiveness of antimicrobials. *Lancet*. 2015 Nov 17.
46. Årdal C, Røttingen J-A. An Open Source Business Model for Malaria. *PLOS ONE* 2015 10(2): e0117150.
47. Røttingen JA, et al. Mapping of available health research and development data: what's there, what's missing, and what role is there for a global observatory? *Lancet*. 2013, 382(9900): 1286-1307.
48. Årdal C, Røttingen JA. Open Source Drug Discovery in Practice: A Case Study. *PLoS Neglected Tropical Diseases* 2012, 6(9): e1827.
49. Årdal C, Alstadsæter A, Røttingen JA. Common characteristics of open source software development and applicability for drug discovery: a systematic review. *Health Research Policy and Systems* 2011, 9:36.
50. Årdal C, Iversen JH, Myhr K. Nye modeller for utvikling av legemidler for fattige land. (New models for developing medicines needed in low-income countries.) *Tidsskrift for Den norske legeförening*, September 2011.
51. Årdal C, Haffeld J, Røttingen JA. Patentering av offentlig finansiert innovasjon? (Patenting of publicly funded innovation?) *Nytt Norsk Tidsskrift* 2011 2: 135-145.

## Projects

EU Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections

DRIVE-AB

## Memberships

## Other Relevant Information